Monoclonal full-length antibody against TDP-43

- Posted in English by

Dr. Silvia Pozzi, Jean-Pierre Julien and colleagues have designed a second antibody therapy against misplaced TDP-43, the most obvious cellular problem in ALS. enter image description here

2020 has seen several announcements in this area, which could create a vaccine against ALS. Penetrating the cell is a challenge. Promis neurosciences had announced that they designed a peptide (a tiny protein) targeting TDP-43, and JP Julien's lab worked on single chain antibodies. Single chain antibodies are miniaturized antibodies, their size is roughly half of a normal antibody.

Now JP Julien's team now announced that they successfully designed and tested a monoclonal antibody on a mice model of the disease. Some signs that they have hope it may progress towards clinical trials is that they tested several administration modes and applied for a patent (US 15/532,909).

This is great news and a further step toward a vaccine, as monoclonal antibodies production is well controlled.


This book retraces the main achievements of ALS research over the last 30 years, presents the drugs under clinical trial, as well as ongoing research on future treatments likely to be able stop the disease in a few years and to provide a complete cure in a decade or two.

Please, to help us continue to provide valuable information: